Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human albumin treatment in adult septic shock
2022-001949-20Phase 2Completed
- Sponsor
- ALBIMMUNE S.L.
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of albumin (human) in septic shock (2 arms), sponsored by ALBIMMUNE S.L. Primary endpoint: Primary: B-cell and other immune cell response scores. Started Sep 2022; status: completed.
02
Drugs
albumin (human)
03
Conditions
septic shock
Beyond the preview
Go deeper on 2022-001949-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001949-20.